Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-58067 |
| Synonyms | |
| Therapy Description |
BGB-58067 selectively inhibits PRMT5 in MTAP-deleted cells, which potentially leads to decreased tumor cell growth (Cancer Res (2025) 85 (8_Supplement_2): CT193, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-58067 | BGB58067|BGB 58067 | PRMT5 Inhibitor 21 | BGB-58067 selectively inhibits PRMT5 in MTAP-deleted cells, which potentially leads to decreased tumor cell growth (Cancer Res (2025) 85 (8_Supplement_2): CT193, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06589596 | Phase I | BG-89894 + BGB-58067 BGB-58067 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | DNK | AUS | 2 |